General information, not legal or regulatory advice. Sources were checked on 28 September 2026. bioaccess® does not run studies in Kazakhstan and is not affiliated with any company named here.
If you searched for “Kazakhstan device trial approval”, you probably want to know who approves an interventional medical device study there, what standards apply, and whether it makes sense for a first-in-human (FIH) or early feasibility study (EFS). This page summarizes the framework from public legal sources and then compares it fairly with a Latin American start.
Who approves an interventional device trial
A legal overview published on Legal 500 describes three steps:
- Expert review. The National Center for Expertise of Medicines and Medical Devices examines the clinical trial materials and issues a conclusion.
- Bioethics review. The Central Commission on Bioethics reviews interventional trials of foreign-produced medicines and devices, as well as trials at two or more centers in Kazakhstan. Local bioethics commissions handle single-center studies, except interventional trials of products made outside Kazakhstan. For a foreign device FIH, plan on the Central Commission.
- Permission. The Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare issues the permit and conducts clinical-trial inspections.
The legal framework
The same overview lists the main instruments:
- The Code on Public Health and the Healthcare System (No. 360-VI, 7 July 2020).
- The Eurasian Economic Union (EAEU) Rules of Good Clinical Practice (Decision No. 79, 3 November 2016) and Kazakhstan’s own good clinical practice (GCP) standard (Order ҚР ДСМ-15, 4 February 2021).
- ISO 14155 through Eurasian Economic Commission Recommendation No. 17 (4 September 2017) on device trials involving human subjects.
- The rules for conducting clinical trials and the requirements for clinical sites (Order ҚР ДСМ-248/2020, 11 December 2020).
Other points from the overview that matter for planning:
- Site requirements: a medical license, standard operating procedures (SOPs) for trials, suitable equipment or contracted services, GCP-trained staff, and intensive care capability where the protocol requires it.
- Participant restrictions: interventional trials may not enroll military or law-enforcement personnel, employees of the medical organization where the research takes place, or people in penal institutions.
- Records: the sponsor and investigator must archive trial documents for 25 years after completion.
- The overview notes that draft amendments were under public discussion when it was published, so confirm the current text.
What is published about timelines
We did not find an official, device-specific end-to-end timeline in the sources above. Ask for a written calendar that covers the expert review, the Central Commission on Bioethics and the Ministry permit.
Standards and U.S. data acceptance
The U.S. Food and Drug Administration (FDA) accepts device data from outside the United States under 21 CFR 812.28 when the study is well designed and well conducted under GCP, with independent ethics review and informed consent, and FDA can validate the data. That data can support an investigational device exemption (IDE), 510(k), De Novo or premarket approval (PMA) submission. Kazakhstan’s reference to ISO 14155 fits that expectation. What matters is how the study is actually run.
Patients, sites and device experience
- Population: about 20.6 million (World Bank, 2024).
- ClinicalTrials.gov (28 September 2026): 26 interventional device records list a site in Kazakhstan. None has “device feasibility” as its primary purpose, which suggests early-device experience is still limited.
- Kazakhstan does not appear on Clinical Accelerator’s public coverage map. See our regional comparison.
Recruitment reality: with a thin FIH track record, you will depend more heavily on individual investigators’ experience with your device type. Strict inclusion criteria can shrink eligible pools quickly. Verify screening numbers for your criteria at each named site.
Logistics from the United States
- Time zone: Astana is on UTC+5 (Coordinated Universal Time plus five hours), 9–10 hours ahead of U.S. Eastern time.
- Languages: Kazakh and Russian. Confirm the translation requirements for the protocol and informed consent form (ICF).
- Check the U.S. Department of State travel advisory and current routings.
Genuine strengths
Kazakhstan has a codified framework that explicitly references ISO 14155 and EAEU GCP, a defined inspection authority, clear site requirements, and a mid-sized population. For sponsors who also have Eurasian market plans, running work there can be strategically useful.
How Latin America compares
- Same FDA rule: 21 CFR 812.28.
- Early-device track record: on ClinicalTrials.gov, Panama has 5 records with “device feasibility” as their primary purpose, Chile 4 and Brazil 15.
- Published clocks: our Panama hub publishes 3–5 week ethics approval and a 6–8 week average to first patient with bioaccess® coordination. Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) regulates device clinical investigations under Disposition 969/1997. See our Argentina hub.
- Time zone: 0–2 hours from U.S. Eastern.
- U.S. continuity: bioaccess® is headquartered in Miami, and its sister organization Amavita Research Services runs a Miami device and early feasibility study site.
- Trade-offs: Spanish or Portuguese documents and investigational import permits.
Other country guides: Georgia · Uzbekistan · Armenia · Moldova · Ukraine · Serbia
Frequently asked questions
Who issues permission for a device trial in Kazakhstan?
The Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare issues the permit. It relies on a conclusion from the National Center for Expertise of Medicines and Medical Devices and a bioethics opinion.
Which ethics body reviews a foreign device trial?
For interventional trials of foreign-produced devices, the Central Commission on Bioethics reviews the study, according to the published legal overview.
Does Kazakhstan follow ISO 14155?
Yes. A Eurasian Economic Commission recommendation on device good clinical practice, based on ISO 14155, is part of the framework.
Will the FDA accept data from Kazakhstan?
It can. Under 21 CFR 812.28, FDA accepts data from outside the United States from studies run under GCP that it can validate. The decision is made case by case.
How long does approval take?
We found no official device-specific figure. Ask for a written calendar.
Next step
Comparing Kazakhstan with a Latin American start? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.